Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector
Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results -- Update
Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...
Novo’s New Obesity Drug Disappoints Again, This Time in Diabetes
Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot ...
STAT57m
Pharmalittle: We’re reading about HHS buyout offers, a Novo obesity trial, and more
Most HHS workers were emailed an offer to leave their job for as much as $25,000 as part of President Trump’s government cuts ...
Eating disorder a serious issue among State’s teenagers, say experts
The death of an 18-year-old girl in Kannur reportedly following extreme dieting and subsequent medical complications, possibly due to an eating disorder, has brought the focus sharply on the serious ...